Abstract
Cancer immunoediting is a process by which immune cells, particularly lymphocytes of the adaptive immune system, protect the host from the development of cancer and alter tumour progression by driving the outgrowth of tumour cells with decreased sensitivity to immune attack1,2. Carcinogen-induced mouse models of cancer have shown that primary tumour susceptibility is thereby enhanced in immune-compromised mice, whereas the capacity for such tumours to grow after transplantation into wild-type mice is reduced2,3. However, many questions about the process of cancer immunoediting remain unanswered, in part because of the known antigenic complexity and heterogeneity of carcinogen-induced tumours4. Here we adapted a genetically engineered, autochthonous mouse model of sarcomagenesis to investigate the process of cancer immunoediting. This system allows us to monitor the onset and growth of immunogenic and non-immunogenic tumours induced in situ that harbour identical genetic and histopathological characteristics. By comparing the development of such tumours in immune-competent mice with their development in mice with broad immunodeficiency or specific antigenic tolerance, we show that recognition of tumour-specific antigens by lymphocytes is critical for immunoediting against sarcomas. Furthermore, primary sarcomas were edited to become less immunogenic through the selective outgrowth of cells that were able to escape T lymphocyte attack. Loss of tumour antigen expression or presentation on major histocompatibility complex I was necessary and sufficient for this immunoediting process to occur. These results highlight the importance of tumour-specific-antigen expression in immune surveillance, and potentially, immunotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991–998 (2002)
Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001)
Swann, J. B. et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl Acad. Sci. USA 105, 652–656 (2008)
Qin, Z. & Blankenstein, T. A cancer immunosurveillance controversy. Nature Immunol. 5, 3–4 (2004); author reply. 5, 4–5 (2004)
Kirsch, D. G. et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Med. 13, 992–997 (2007)
DuPage, M. et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19, 72–85 (2011)
Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907 (2007)
Cheung, A. F., Dupage, M. J., Dong, H. K., Chen, J. & Jacks, T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res. 68, 9459–9468 (2008)
Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nature Immunol. 3, 999–1005 (2002)
Prehn, R. T. & Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18, 769–778 (1957)
Dubey, P. et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med. 185, 695–705 (1997)
Monach, P. A., Meredith, S. C., Siegel, C. T. & Schreiber, H. A unique tumor antigen produced by a single amino acid substitution. Immunity 2, 45–59 (1995)
Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Naturehttp://dx.doi.org/10.1038/nature10755 (this issue)
Uyttenhove, C., Maryanski, J. & Boon, T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040–1052 (1983)
Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I. & Marson, A. L. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 200, 1581–1592 (2004)
Stauss, H. J., Van Waes, C., Fink, M. A., Starr, B. & Schreiber, H. Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. J. Exp. Med. 164, 1516–1530 (1986)
Guo, Z. S. et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 66, 1105–1113 (2006)
Güre, A. O., Wei, I. J., Old, L. J. & Chen, Y. T. The SSX gene family: characterization of 9 complete genes. Int. J. Cancer 101, 448–453 (2002)
Guerra, N. et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571–580 (2008); correction. 28, 723 (2008)
Schietinger, A. et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314, 304–308 (2006)
Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Rev. Immunol. 6, 715–727 (2006)
Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141–146 (2005)
Embleton, M. J. & Heidelberger, C. Antigenicity of clones of mouse prostate cells transformed in vitro. Int. J. Cancer 9, 8–18 (1972)
Hewitt, H. B., Blake, E. R. & Walder, A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33, 241–259 (1976)
Scott, O. C. Tumor transplantation and tumor immunity: a personal view. Cancer Res. 51, 757–763 (1991)
Rangarajan, A. & Weinberg, R. A. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev. Cancer 3, 952–959 (2003)
DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protocols 4, 1064–1072 (2009)
Acknowledgements
We thank M. M. Winslow and A. G. DuPage for critical reading of this manuscript. This work was supported by grant 1 U54 CA126515-01 from the NIH, and partially by Cancer Center Support (core) grant P30-CA14051 from the National Cancer Institute and the Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award (M.D.) from the John D. Proctor Foundation. T.J. is a Howard Hughes Investigator and a Daniel K. Ludwig Scholar.
Author information
Authors and Affiliations
Contributions
M.D. and T.J. designed the study. M.D. performed all experiments with assistance from C.M. and L.M.S. A.F.C. provided reagents and conceptual advice. M.D. and T.J. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figures
This file contains Supplementary Figures 1-4 with legends. (PDF 536 kb)
Rights and permissions
About this article
Cite this article
DuPage, M., Mazumdar, C., Schmidt, L. et al. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405–409 (2012). https://doi.org/10.1038/nature10803
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature10803
This article is cited by
-
Regulation of immunological tolerance by the p53-inhibitor iASPP
Cell Death & Disease (2023)
-
Oncogenic drivers dictate immune control of acute myeloid leukemia
Nature Communications (2023)
-
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
Nature Genetics (2023)
-
A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
Cell Death Discovery (2023)
-
Peripheral blood-based cell signature indicates response to interstitial brachytherapy in primary liver cancer
Journal of Cancer Research and Clinical Oncology (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.